Now I have sufficient information. Let me write the final consolidated review.

## Summary

This paper introduces NormIntSleep, a framework that projects deep neural network embeddings onto a clinically grounded feature space (FeatShort, derived from AASM sleep scoring guidelines) via a learned linear projector, enabling glass-box models like decision trees to produce interpretable sleep stage classifications. The paper also proposes AlignmentDT, a metric to quantify how well a decision tree's splits align with domain knowledge. NormIntSleep-DecisionTree improves accuracy over FeatShort-DecisionTree from 75.8%→81.9% (PhysioNet) and 69.8%→79.1% (ISRUC), and achieves AlignmentDT=1.0, which is validated by a practicing sleep clinician.

## Strengths

- **NormIntSleep substantially boosts decision-tree accuracy while preserving interpretability**: The improvement from FeatShort-DecisionTree to NormIntSleep-DecisionTree is large (+6.1% on PhysioNet, +9.3% on ISRUC) and is achieved while maintaining a fully transparent glass-box model. This is a clean empirical demonstration that the projection of DNN embeddings onto the clinical feature space provides real value for interpretable classification. (Line 163: accuracy improvement from 75.8% to 81.9% on PhysioNet; 69.8% to 79.1% on ISRUC.)

- **Clinician validation of the decision tree**: A practicing sleep specialist reviewed each node's logic and confirmed that the splits mirror clinical decision-making — beta waves identifying Wake, EOG crossings for Wake/REM, slow waves for N3, etc. (Section 5.1, lines 176–183). This is stronger evidence than typical plausibility checks and independently supports the claim of clinically meaningful structure.

- **SHAP analysis provides converging evidence**: Section 5.3 (lines 192–202) uses SHAP values to independently identify the most important features in NormIntSleep-XGBoost, and these align with both the decision tree splits and clinical guidelines (EOG complexity for REM, beta waves for Wake, EEG variance for N3). The dual corroboration from two different explanation methods strengthens the interpretability case.

- **AlignmentDT provides a concrete, quantitative measure of domain-grounded interpretability**: The metric is a novel contribution, and the scores (NormIntSleep=1.0, FeatLong=0, SERF=0.44) make the differences in clinical relevance explicit rather than relying on qualitative claims alone.

## Weaknesses

### Fatal
None.

### Major

- **The interpretable representations are not validated as faithful proxies for clinical features (Structural gap)**. The core mechanism is a linear projector T learned via least-squares mapping DNN embeddings E(X) to handcrafted clinical features F_N(X). The paper then interprets tree splits in terms of clinical features — "beta waves," "EOG crossings," "slow waves" — as if each projected dimension corresponds to its named clinical quantity. However, **the paper provides zero analysis of how well this projection works** (no correlation coefficients, no R² values, no reconstruction error on held-out data). A 512-dim embedding linearly projected onto 52–121 features via least-squares may not faithfully preserve each feature's semantics. Without this validation, the central interpretability claim — that explanations are "grounded in clinical guidelines" — rests on an unverified assumption. The clinician review (Section 5.1) provides some indirect support, but it does not substitute for a direct fidelity check.

- **Missing critical ablation: decision tree on raw DNN embeddings**. The paper does not include a control experiment where a decision tree is trained directly on the raw 512-dimensional DNN embeddings (without the linear projection). If such a tree also produces clinically sensible splits, the projection step would be unnecessary for interpretability; if it is unintelligible, the projection's value is demonstrated. Without this ablation, the source of interpretability cannot be cleanly attributed to the NormIntSleep framework versus the inherent properties of the DNN representation. The paper mentions "Ablation Studies" (line 78) but the specific control of raw-embedding trees is not presented in the available text.

### Minor

- **Abstract overclaims outperformance**. The abstract states: "NormIntSleep outperforms prior interpretable techniques with 0.814–0.847 accuracy." However, FeatLong-CatBoost (classified by the paper as an "interpretable benchmark" at line 150) achieves 0.811–0.862 accuracy, with an upper bound exceeding NormIntSleep. The paper acknowledges this in the results section ("the sole exception of the exhaustive feature list present in FeatLong," line 163), but the abstract and contribution list (point 5: "NormIntSleep outperforms other approaches that aim for clinically relevant interpretations") make unqualified claims. This framing mismatch is misleading.

- **Single train-test split with no cross-validation**. The evaluation uses a single 9:1 subject-level split with a fixed seed (line 126). For datasets with 100–197 subjects, this provides no estimate of variance. Confidence intervals are deferred to stripped appendices (Appendix I), but variance information should be in the main results. This limits the reliability of reported performance comparisons.

- **Interpretability analysis restricted to the shallow decision tree**. The clinician review and AlignmentDT calculation are performed on a depth-4 decision tree achieving ~79% accuracy (Section 5.1, Figure 2). The stronger results (0.814–0.847 accuracy) come from the CatBoost variant, which is a substantially more complex ensemble model. The paper implies that interpretability extends to all glass-box variants, but CatBoost's inner workings are not transparent in the same way as a depth-4 tree. The interpretability claim is thus strongest for the variant with the lowest accuracy.

- **Feature count discrepancy across datasets limits generalizability**. FeatShort has 121 features for ISRUC and 52 for PhysioNet (line 94), because ISRUC has two EOG channels while PhysioNet has one. This means the interpretable representation has different dimensionality and semantics across datasets, which is not discussed as a limitation.

- **Double-fitting risk not discussed**. The DNN and the linear projector T are both fit to the same training data (the DNN end-to-end on sleep staging, then T via least-squares on the same training set's embeddings). The paper does not discuss whether this introduces overfitting or how it is mitigated.

### Trivial
None.

## Nice-to-Haves

- The paper would benefit from a dedicated limitations section acknowledging the unvalidated projection quality, single-split evaluation, and the shallow-tree → CatBoost interpretability gap discussed above.
- Cross-validation (or at minimum, results across multiple random splits) would strengthen the quantitative claims.
- The AlignmentDT metric definition is described only in prose in the parsed text; the equation is missing from the available version.

## Removed Points

These points were identified by the reviewers but are removed following the filtering rules:

- **"AlignmentDT is circularly favorable"** (removed as overstated): The metric measures alignment with clinical guidelines. NormIntSleep is designed to align with those same guidelines. This is a design property, not a circularity — the metric measures what it claims to. However, the point about unfair comparison with FeatLong (which was never designed for clinical alignment) is valid and subsumed under the abstract-overclaiming weakness above.
- **"95% single-stage exclusion threshold is arbitrary"** (removed): The paper provides justification: these nodes "behave similar to a leaf node" and "do not play a major role in the overall model behavior." The justification may be debated but is present; the claim of "without justification" is factually incorrect.
- **Missing equation for AlignmentDT** (removed as parser issue): The original PDF contains the equation; the parser stripped the image.
- **Reproducibility: hyperparameters too sparse** (removed): The paper provides kernel sizes (201, 11, 11), channels (256, 128, 64), LSTM hidden states (256), batch size (1000), epochs (50), learning rate (1e-4), and optimizer (Adam). This is adequate for a paper of this scope.
- **References to stripped appendices** (removed as parser issue): The appendices exist in the original submission; the parser stripped them.
- **Strength: "Modular architecture for domain portability"** (removed as generic): The paper claims modularity but does not demonstrate or evaluate portability to another domain.
- **Strength: "Outperforms all prior interpretable methods"** (removed as conflicting with verified weakness): The claim is contradicted by FeatLong-CatBoost's superior performance on the upper bound.

## Novel Insights

The most interesting observation arising from the reviews is the tension between the paper's two strongest pieces of evidence — the clinician's tree validation and the AlignmentDT metric — and the central gap they leave open. The clinician confirms that the decision tree's *splits* make clinical sense, and AlignmentDT quantifies this alignment. But neither addresses whether the *projected dimensions* actually correspond to the clinical features they are named after. This means the paper provides good evidence that its models produce clinically meaningful classification *rules* (the tree structure is sensible) but weaker evidence that it produces clinically meaningful *features* (the "beta wave" dimension may not encode beta wave power). These are distinct claims, and the paper conflates them. A correlation analysis between projected dimensions and ground-truth clinical features would cleanly close this gap.

## Suggestions

1. **Validate projection fidelity**: Compute the Spearman correlation or R² between each dimension of R(X) and its corresponding clinical feature from FeatShort on held-out data. If correlations are high (e.g., >0.7), the interpretability claim is strongly supported. Report the distribution of these correlations across all feature dimensions.

2. **Add the missing ablation**: Train a decision tree directly on raw 512-dim DNN embeddings and report both its accuracy and AlignmentDT score. Compare to NormIntSleep-DecisionTree and FeatShort-DecisionTree. This isolates the projection's contribution.

3. **Fix the framing**: Qualify the "outperforms" claim in the abstract and contributions to explicitly note that FeatLong-CatBoost achieves higher accuracy on the upper bound but uses 10–20× more features that are not clinically grounded.

4. **Report variance**: Add cross-validation results or multiple random splits with mean and standard deviation. Even 5-fold by-subject cross-validation would substantially strengthen the reliability of the quantitative claims.

5. **Acknowledge limitations explicitly**: Add a limitations subsection addressing the projection validation gap, the single-split evaluation, and the gap between the analyzed depth-4 tree and the higher-performing CatBoost ensemble.

## Score and Decision

MY FINAL SCORE: <score>5.0</score>
MY FINAL DECISION: <decision>Reject</decision>